🚀 VC round data is live in beta, check it out!
MiMedx Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for MiMedx Group and similar public comparables like CytoDyn, Sofwave Medical, Contineum Therapeutics, Orthofix Medical and more.
MiMedx Group Overview
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Founded
2008
HQ
Employees
837
Website
Financials (LTM)
EV
$359M
MiMedx Group Financials
MiMedx Group reported last 12-month revenue of $390M and EBITDA of $87M.
In the same LTM period, MiMedx Group generated $319M in gross profit, $87M in EBITDA, and $36M in net income.
Revenue (LTM)
MiMedx Group P&L
In the most recent fiscal year, MiMedx Group reported revenue of $419M and EBITDA of $105M.
MiMedx Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $390M | XXX | $419M | XXX | XXX | XXX |
| Gross Profit | $319M | XXX | $346M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $87M | XXX | $105M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $36M | XXX | $49M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MiMedx Group Stock Performance
MiMedx Group has current market cap of $507M, and enterprise value of $359M.
Market Cap Evolution
MiMedx Group's stock price is $3.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $359M | $507M | 0.0% | XXX | XXX | XXX | $0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMiMedx Group Valuation Multiples
MiMedx Group trades at 0.9x EV/Revenue multiple, and 4.1x EV/EBITDA.
EV / Revenue (LTM)
MiMedx Group Financial Valuation Multiples
As of April 20, 2026, MiMedx Group has market cap of $507M and EV of $359M.
Equity research analysts estimate MiMedx Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MiMedx Group has a P/E ratio of 14.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $507M | XXX | $507M | XXX | XXX | XXX |
| EV (current) | $359M | XXX | $359M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 4.1x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBIT | 6.3x | XXX | 4.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | 1.0x | XXX | XXX | XXX |
| P/E | 14.2x | XXX | 10.4x | XXX | XXX | XXX |
| EV/FCF | 7.4x | XXX | 4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MiMedx Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MiMedx Group Margins & Growth Rates
MiMedx Group's revenue in the last 12 month declined by (14%).
MiMedx Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
MiMedx Group's rule of 40 is (9%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MiMedx Group's rule of X is (43%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
MiMedx Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (14%) | XXX | (23%) | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | (39%) | XXX | (57%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (9%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (43%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | 67% | XXX | 67% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MiMedx Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CytoDyn | XXX | XXX | XXX | XXX | XXX | XXX |
| Sofwave Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Contineum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthofix Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexeo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MiMedx Group M&A Activity
MiMedx Group acquired XXX companies to date.
Last acquisition by MiMedx Group was on XXXXXXXX, XXXXX. MiMedx Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MiMedx Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMiMedx Group Investment Activity
MiMedx Group invested in XXX companies to date.
MiMedx Group made its latest investment on XXXXXXXX, XXXXX. MiMedx Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MiMedx Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MiMedx Group
| When was MiMedx Group founded? | MiMedx Group was founded in 2008. |
| Where is MiMedx Group headquartered? | MiMedx Group is headquartered in United States. |
| How many employees does MiMedx Group have? | As of today, MiMedx Group has over 837 employees. |
| Who is the CEO of MiMedx Group? | MiMedx Group's CEO is Joseph H. Capper. |
| Is MiMedx Group publicly listed? | Yes, MiMedx Group is a public company listed on Nasdaq. |
| What is the stock symbol of MiMedx Group? | MiMedx Group trades under MDXG ticker. |
| When did MiMedx Group go public? | MiMedx Group went public in 2007. |
| Who are competitors of MiMedx Group? | MiMedx Group main competitors are CytoDyn, Sofwave Medical, Contineum Therapeutics, Orthofix Medical. |
| What is the current market cap of MiMedx Group? | MiMedx Group's current market cap is $507M. |
| What is the current revenue of MiMedx Group? | MiMedx Group's last 12 months revenue is $390M. |
| What is the current revenue growth of MiMedx Group? | MiMedx Group revenue growth (NTM/LTM) is (14%). |
| What is the current EV/Revenue multiple of MiMedx Group? | Current revenue multiple of MiMedx Group is 0.9x. |
| Is MiMedx Group profitable? | Yes, MiMedx Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MiMedx Group? | MiMedx Group's last 12 months EBITDA is $87M. |
| What is MiMedx Group's EBITDA margin? | MiMedx Group's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of MiMedx Group? | Current EBITDA multiple of MiMedx Group is 4.1x. |
| What is the current FCF of MiMedx Group? | MiMedx Group's last 12 months FCF is $49M. |
| What is MiMedx Group's FCF margin? | MiMedx Group's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of MiMedx Group? | Current FCF multiple of MiMedx Group is 7.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.